Payment overview · 2025
General Payments
$2,125.97
129 reported records · 20 companies
Healthcare provider profile · identity verified
Amy Guan, MS, APN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Gerontology · SAINT LOUIS, MO · NPI 1801398813
Verified facts
What the public records show
CMS Open Payments records show Amy Guan, MS, APN received $2,125.97 in general payments during 2025 across 129 reported records.
Lilly USA, LLC accounted for 15.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Paxlovid, Rexulti.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $328.65 | 15.5% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $269.24 | 12.7% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $258.61 | 12.2% | 14 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $196.50 | 9.2% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $188.65 | 8.9% | 11 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $181.23 | 8.5% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $143.75 | 6.8% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $135.13 | 6.4% | 12 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $77.91 | 3.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $54.59 | 2.6% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.57 | 2.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $39.01 | 1.8% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $35.08 | 1.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.95 | 1.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.81 | 1.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.10 | 1.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $22.36 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.41 | 0.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.43 | 0.8% | 1 | 2025 |
| Valinor Pharma, LLC | Unresolved — no canonical attribution shown | $13.99 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,125.97 | 129 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $377.73 | 24 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $280.51 | 18 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $154.67 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $135.84 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $115.34 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $102.91 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $100.84 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $100.28 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $84.67 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $83.36 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $81.32 | 9 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $79.33 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $77.91 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $76.16 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $75.61 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $64.42 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $50.57 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.35 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $42.05 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.05 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $39.01 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $38.00 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $35.08 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.29 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.29 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.29 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.81 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.68 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.10 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| MOVANTIK Normalized: movantik |
Drug | Valinor Pharma, LLC | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 19 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
25 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 98 | 86 |
| Prednisone | Prednisone | 84 | 74 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 55 |
| Atorvastatin Calcium | Atorvastatin Calcium | 81 | 37 |
| Gabapentin | Gabapentin | 55 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 53 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 43 | 21 |
| Trazodone Hcl | Trazodone Hcl | 42 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 27 |
| Buspirone Hcl | Buspirone Hcl | 40 | 15 |
| Clindamycin Hcl | Clindamycin Hcl | 37 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 31 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 30 |
| Sertraline Hcl | Sertraline Hcl | 34 | 16 |
| Losartan Potassium | Losartan Potassium | 31 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 23 |
| Meloxicam | Meloxicam | 30 | 13 |
| Famotidine | Famotidine | 27 | 14 |
| Lisinopril | Lisinopril | 27 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 27 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 26 | 18 |
| Eliquis | Apixaban | 25 | 12 |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Furosemide | Furosemide | 22 | 14 |
| Ondansetron Odt | Ondansetron | 22 | 16 |
| Azithromycin | Azithromycin | 20 | 18 |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Jardiance | Empagliflozin | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 14 |
| Gemtesa | Vibegron | 14 | suppressed |
| Metformin Hcl | Metformin Hcl | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Cefdinir | Cefdinir | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,125.97 · 129 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, COMIRNATY, Cologuard Collection Kit, EVENITY, FANAPT, FARXIGA, GEMTESA, INSPIRE, JARDIANCE, KISUNLA, Kerendia, Korlym, MOUNJARO, MOVANTIK, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error